Study details
Enrolling now
Imaging Depression in Parkinson's Disease
Yale University
NCT IDNCT06402955ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
120
Study length
about 4.1 years
Ages
40–80
Locations
1 site in CT
About this study
Researchers are testing whether imaging can help identify the brain areas that cause depression in people with Parkinson's disease. The trial will use scans to look at how different parts of the brain are working when people experience depression. It involves adults aged 40-80 experiencing symptoms of depression.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive 11C-UCB-J
- 2.Take ketamine hydrochloride
PhasePhase 2
Drugketamine hydrochloride
Primary goalMontgomery-Åsberg Depression Rating Scale (MADRS)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
Anesthetics (Dopamine Agonists)
Endpoints
Primary: Montgomery-Åsberg Depression Rating Scale (MADRS)
Body systems
Neurology, Psychiatry / Mental Health